Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection
- PMID: 35124108
- DOI: 10.1016/j.jhep.2022.01.017
Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection
Conflict of interest statement
Conflict of interest M.J. served as a speaker for Gilead. B.S. received travel support from AbbVie, Ipsen and Gilead. M.P. is an investigator for Bayer, BMS, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, Lilly, MSD, and Roche; he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Systemic treatment of hepatocellular carcinoma: An EASL position paper.J Hepatol. 2021 Oct;75(4):960-974. doi: 10.1016/j.jhep.2021.07.004. Epub 2021 Jul 10. J Hepatol. 2021. PMID: 34256065
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
